Principia payoff

With one preclinical deal, Human Genome Sciences Inc. stands to have monetized its acquisition of Principia Pharmaceuticals Corp.

HGSI bought Principia in 2000 for $120 million in stock in order to gain access to its human albumin-based protein fusion technology. Last week, GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.)

Read the full 487 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE